Evidence map›Paper›PMID 32788346›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition.

Patrick Ming-Kuen Tang, Ying-Ying Zhang, Jun Xiao, Philip Chiu-Tsun Tang, Jeff Yat-Fai Chung, Jinhong Li, Vivian Weiwen Xue, Xiao-Ru Huang, Charing Ching-Ning Chong, Chi-Fai Ng and 4 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 111 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Patrick Ming-Kuen TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 999077, Hong Kong; patrick.tang@cuhk.edu.hk hylan@cuhk.edu.hk.ORCID 0000-0002-3194-3736
Ying-Ying ZhangDepartment of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, 999077, Hong Kong.
Jun XiaoDepartment of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, 999077, Hong Kong.ORCID 0000-0003-4004-3382
Philip Chiu-Tsun TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 999077, Hong Kong.
Jeff Yat-Fai ChungDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 999077, Hong Kong.
Jinhong LiDepartment of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, 999077, Hong Kong.
Vivian Weiwen XueDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 999077, Hong Kong.
Xiao-Ru HuangDepartment of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, 999077, Hong Kong.
Charing Ching-Ning ChongSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, 999077, Hong Kong.ORCID 0000-0002-8425-8767
Chi-Fai NgSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, 999077, Hong Kong.ORCID 0000-0002-1723-9646
Tin-Lap LeeReproduction, Development and Endocrinology Program, School of Biomedical Sciences, The Chinese University of Hong Kong, 999077, Hong Kong.
Ka-Fai ToDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 999077, Hong Kong.
David J Nikolic-PatersonDepartment of Nephrology and Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia.ORCID 0000-0001-5734-2931
Hui-Yao LanDepartment of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, 999077, Hong Kong; patrick.tang@cuhk.edu.hk hylan@cuhk.edu.hk.
Chinese University of Hong Kong · HKTongji University · CNMonash Medical Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unresolved inflammation can lead to tissue fibrosis and impaired organ function. Macrophage-myofibroblast transition (MMT) is one newly identified mechanism by which ongoing chronic inflammation causes progressive fibrosis in different forms of kidney disease. However, the mechanisms underlying MMT are still largely unknown. Here, we discovered a brain-specific homeobox/POU domain protein Pou4f1 (Brn3a) as a specific regulator of MMT. Interestingly, we found that Pou4f1 is highly expressed by macrophages undergoing MMT in sites of fibrosis in human and experimental kidney disease, identified by coexpression of the myofibroblast marker, α-SMA. Unexpectedly, Pou4f1 expression peaked in the early stage in renal fibrogenesis in vivo and during MMT of bone marrow-derived macrophages (BMDMs) in vitro. Mechanistically, chromatin immunoprecipitation (ChIP) assay identified that Pou4f1 is a Smad3 target and the key downstream regulator of MMT, while microarray analysis defined a Pou4f1-dependent fibrogenic gene network for promoting TGF-β1/Smad3-driven MMT in BMDMs at the transcriptional level. More importantly, using two mouse models of progressive renal interstitial fibrosis featuring the MMT process, we demonstrated that adoptive transfer of TGF-β1-stimulated BMDMs restored both MMT and renal fibrosis in macrophage-depleted mice, which was prevented by silencing Pou4f1 in transferred BMDMs. These findings establish a role for Pou4f1 in MMT and renal fibrosis and suggest that Pou4f1 may be a therapeutic target for chronic kidney disease with progressive renal fibrosis.

Indexed as

AnimalsFemaleFibrosisGene Regulatory NetworksHumansInflammationKidneyKidney DiseasesMacrophagesMaleMiceMice, Inbred C57BLMyofibroblastsSignal TransductionSmad3 ProteinTranscription Factor Brn-3APOU4F1 protein, humanPou4f1 protein, mouseSmad3 ProteinSMAD3 protein, humanTGFB1 protein, humanTranscription Factor Brn-3ATransforming Growth Factor betaTransforming Growth Factor beta1macrophage–myofibroblast transitionPou4f1renal fibrosis

Identifiers

PMID32788346
PMCPMC7456094
OpenAlexW3048419072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.